Back

Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy in HELIOS-B who had progressed on tafamidis

20 May 2025 (09:21 - 09:30)
Organised by: Logo
Congress Presentation Part of: Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jose Gonzalez-Costello

Bellvitge University Hospital, Hospitalet De Llobregat (Spain)

6 More presentations in this session

Presentation thumbnail
Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registry
Doctor G. Ferrannini (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM
Doctor A. Ducharme (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Metabolic effects of 14-day oral ketone ester treatment in patients with heart failure with reduced ejection fraction
Mr K. Berg-Hansen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Outcome and disease progression in patients with wild-type transthyretin cardiomyopathy treated with tafamidis
Associate Professor A. Cipriani (Padua, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
Video

The Event

Event poster

Heart Failure 2025

20 May 2025 09:21 CET
You may be interested in
thumbnail
Congress Presentation
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis
thumbnail
Congress Session
Transthyretin amyloidosis: long-term outcomes and emerging therapies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources